<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Eravacycline: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Eravacycline: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Eravacycline: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="118919" href="/d/html/118919.html" rel="external">see "Eravacycline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51945157"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Xerava</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F51820589"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Tetracycline Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F51962754"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection (alternative agent):</b>
<b>IV:</b> 1 mg/kg every 12 hours; total duration of therapy (which may include transition to oral antibiotics) is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31944332','lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31944332','lexi-content-ref-29090866','lexi-content-ref-25992746','lexi-content-ref-28085573','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f89dada3-8df7-4d1e-a7e5-73510586d7c9">Plague, bubonic or pharyngeal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague (<i>Yersinia pestis</i>), bubonic or pharyngeal (alternative agent) (off-</b>
<b>label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 mg/kg every 12 hours for 10 to 14 days or longer based on clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F51962756"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F51962757"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): 1 mg/kg every 12 hours on day 1, then 1 mg/kg every 24 hours</p></div>
<div class="block doe drugH1Div" id="F51962755"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F51822129"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (7%), vomiting (4%), diarrhea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion site reaction (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound dehiscence (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute pancreatitis, anaphylaxis, anxiety, chest pain, decreased creatinine clearance, decreased white blood cell count, depression, dizziness, dysgeusia, dyspnea, hyperhidrosis, hypersensitivity reaction, hypocalcemia, increased amylase, increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum lipase, insomnia, neutropenia, palpitations, pancreatic necrosis, pleural effusion, prolonged partial thromboplastin time, skin rash</p></div>
<div class="block coi drugH1Div" id="F51820592"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to eravacycline, tetracycline-class antibacterial drugs, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F51962741"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactic/Hypersensitivity reactions: Life-threatening (anaphylactic) reactions have been reported; discontinue if an allergic reaction occurs. Avoid use in patients with known hypersensitivity to tetracyclines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antianabolic effects: May be associated with antianabolic effects observed with the tetracycline class (including increased BUN, azotemia, acidosis, and hyperphosphatemia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: May be associated with abnormal liver function tests due to structural similarities with tetracyclines; discontinue use when suspected.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: May be associated with pancreatitis due to structural similarities with tetracyclines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: May be associated with photosensitivity due to structural similarities with tetracyclines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pseudotumor cerebri: May be associated with pseudotumor cerebri due to structural similarities with tetracyclines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Use may result in fungal or bacterial superinfection, including <i>Clostridioides</i>
<i>difficile </i>infection (CDI) and colitis; CDI has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May cause permanent tooth discoloration, enamel hypoplasia, or reversible inhibition of bone growth; use should be avoided during tooth and bone development (children &lt;8 years of age).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Limitations of use: Not indicated for the treatment of complicated urinary tract infection in adults; eravacycline failed to demonstrate efficacy in 2 randomized, double-blind, active-controlled clinical trials.</p></div>
<div class="block foc drugH1Div" id="F51945158"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xerava: 50 mg (1 ea); 100 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F51945156"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52042922"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Xerava Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $73.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $132.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F51962759"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Infuse diluted solution IV over ~60 minutes through dedicated line or via Y-site. If the same IV line is used for sequential infusion of several drugs, flush line with NS before and after eravacycline administration. Do not mix with other drugs or add to solutions containing other drugs.</p></div>
<div class="block use drugH1Div" id="F51820591"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b> Treatment of complicated intra-abdominal infections caused by susceptible microorganisms: <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Citrobacter freundii</i>, <i>Enterobacter cloacae</i>, <i>Klebsiella oxytoca</i>, <i>Enterococcus faecalis</i>, <i>Enterococcus faecium</i>, <i>Staphylococcus aureus</i>, <i>Streptococcus anginosus</i> group, <i>Clostridium perfringens</i>, <i>Bacteroides</i> species, and <i>Parabacteroides distasonis</i> in patients ≥18 years.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not indicated for the treatment of complicated urinary tract infections.</p></div>
<div class="block off-label drugH1Div" id="F57151991"><span class="drugH1">Use: Off-Label: Adult</span><p>Plague (Yersinia pestis)</p></div>
<div class="block cyt drugH1Div" id="F51821987"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F51821984"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Eravacycline. Management: Increase the eravacycline dose to 1.5 mg/kg every 12 hours when combined with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Tetracyclines may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Tetracyclines may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Tetracyclines may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F51962739"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tetracyclines cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">As a class, tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Exposure during the second and third trimesters of pregnancy may cause reversible inhibition of bone growth. Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.</p>
<p style="text-indent:0em;margin-top:2em;">Eravacycline is not one of the recommended antibiotics for the treatment of plague (<i>Y. pestis</i>) in pregnant patients (CDC [Nelson 2021]).</p></div>
<div class="block brc drugH1Div" id="F51962740"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if eravacycline is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Other tetracyclines are present in breast milk; the extent of eravacycline absorption by a breastfeeding infant is not known. Due to the potential for serious adverse reactions in the breastfed infant (including tooth discoloration and inhibition of bone growth), breastfeeding is not recommended by the manufacturer during therapy or for 4 days after the last dose.</p></div>
<div class="block mop drugH1Div" id="F51962762"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor hepatic function periodically. Observe for signs and symptoms of anaphylaxis during administration.</p></div>
<div class="block pha drugH1Div" id="F51962745"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Eravacycline is a fluorocycline antibiotic within the tetracycline class that binds to the 30S ribosomal subunit and prevents the incorporation of amino acid residues into elongating peptide chains, thereby, inhibiting bacterial protein synthesis.</p></div>
<div class="block phk drugH1Div" id="F51962746"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: ~321 L (~4 L/kg) (Newman 2018)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 79% to 90% (increases with increasing plasma concentrations)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily by CYP3A4- and FMO-mediated oxidation</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 20 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: ~34% (20% as unchanged drug); Feces: 47% (17% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51962752"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Hepatic function impairment: C<sub>max</sub> was 13.9%, 16.3%, and 19.7% higher and AUC was 22.9%, 37.9%, and 110.3% higher in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment compared to healthy subjects, respectively.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31944332">
<a name="31944332"></a>Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SCJ, Rybak MJ. Evaluation of eravacycline: a novel fluorocycline. <i>Pharmacotherapy</i>. 2020;40(3):221-238. doi:10.1002/phar.2366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eravacycline-drug-information/abstract-text/31944332/pubmed" id="31944332" target="_blank">31944332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29090866">
<a name="29090866"></a>Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. <i>J Hepatobiliary Pancreat Sci.</i> 2018;25(1):3-16. doi:10.1002/jhbp.518<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eravacycline-drug-information/abstract-text/29090866/pubmed" id="29090866" target="_blank">29090866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eravacycline-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20814687">
<a name="20814687"></a>Mylonas I. Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration. <i>Arch Gynecol Obstet. </i>2011;283(1):7-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eravacycline-drug-information/abstract-text/20814687/pubmed" id="20814687" target="_blank">20814687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS; contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eravacycline-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30150464">
<a name="30150464"></a>Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline [published online August 27, 2018]. <i>Antimicrob Agents Chemother.</i> doi: 10.1128/AAC.01174-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eravacycline-drug-information/abstract-text/30150464/pubmed" id="30150464" target="_blank">30150464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eravacycline-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA), Center for Drug Evaluation and Research. NDA Multi-Disciplinary Review and Evaluation – NDA 211109 Xerava (eravacycline) for injection. 2018. Available at <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf</a>. Accessed February 8, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xerava.1">
<a name="Xerava.1"></a>Xerava (eravacycline) [prescribing information]. Waltham, MA: Tetraphase Pharmaceuticals Inc; July 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 118878 Version 75.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
